Browse studies

Find your next paid study

1 recruiting study matching your filters

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacod…

PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more

Cogent Biosciences, Inc.NCT07383506